“We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core ...

Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the ...

The company said it is evaluating strategic alternatives, including licensing agreements and asset sales, for its therapies ...

Genetics testing company 23andMe is trimming its headcount by 40%. The company said it is undergoing a restructuring to ...

This decision, described by CEO Anne Wojcicki as “difficult but necessary,” comes as the genetic testing company undergoes a ...

As founder and CEO Anne Wojcicki struggles to take the company private, 200 jobs are cut as part of its restructuring plan.

American businesswoman Anne Wojcicki is the co-founder and CEO of genetic testing company 23andMe. She became a billionaire after the company went public in 2021 but since then, the company’s ...

Regarding its workforce reduction, which will total 200 employees, CEO Anne Wojcicki called the layoffs a “difficult but necessary” step to keep the company alive. “We are taking these difficult but ...

Me announced on Monday it would cut 40% of its workforce, representing more than 200 employees, as part of a restructuring at ...

Anne Wojcicki wanted to run things—alone. It was 2009 and her startup 23andMe was riding high, fueled by a steady stream of venture money, intriguing personal accounts of genome exploration ...

Genetic-testing lab 23andMe plans to cut its workforce by 40% and end its therapeutics program in an effort to cut costs, the ...

Andre Fernandez, Jim Frankola and Mark Jensen will join the company's CEO Anne Wojcicki on the board. The new board members ...